Protein-coding Genes And Long Noncoding Rnas Are Differentially Expressed In Dasatinib-treated Chronic Myeloid Leukemia Patients With Resistance To Imatinib

Dasatinib has demonstrated efficacy in patients with chronic-phase chronic myeloid leukemia (CML) who had resistance or intolerance to imatinib. However, some patients also develop resistance or intolerance to dasatinib. To identify potential molecular pathways involved in primary resistance to dasatinib in CML, we analyzed gene expression profiles of mononuclear cells of 7 imatinib-resistant patients, collected before and after 1-year dasatinib treatment. Large-scale gene expression was measured with Agilent microarrays covering protein-coding genes and long (>200 nt) noncoding RNAs (lncRNAs). Sets of genes and lncRNAs significantly differentially expressed (>1.5 fold-change; q value ≤10%) were identified. Ingenuity Pathway Analysis pointed to a number of functions, canonical pathways and gene networks that were significantly enriched with differentially expressed genes. In addition to protein-coding genes, lncRNAs have been recently implicated in pathways leading to tumorigenesis. Our data point to new possible regulatory elements involved in dasatinib resistance in CML. © W. S. Maney & Son Ltd 2014.1913141Gorre, M.E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P.N., Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification (2001) Science, 293, pp. 876-880Branford, S., Rudzki, Z., Walsh, S., Grigg, A., Arthur, C., Taylor, K., High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance (2002) Blood, 99, pp. 3472-3475Shah, N.P., Nicoll, J.M., Nagar, B., Gorre, M.E., Paquette, R.L., Kuriyan, J., Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia (2002) Cancer Cell, 2, pp. 117-125White, D.L., Saunders, V.A., Dang, P., Engler, J., Venables, A., Zrim, S., Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: Higher doses of imatinib may overcome the negative impact of low OCT-1 activity (2007) Blood, 110, pp. 4064-4072Donato, N.J., Wu, J.Y., Stapley, J., Gallick, G., Lin, H., Arlinghaus, R., BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571 (2003) Blood, 101, pp. 690-698Dai, Y., Rahmani, M., Corey, S.J., Dent, P., Grant, S.A., Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2 (2004) J Biol Chem, 279, pp. 34227-34239Lombardo, L.J., Lee, F.Y., Chen, P., Norris, D., Barish, J.C., Behnia, K., Discovery of N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylami-no)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays (2004) J Med Chem, 47, pp. 6658-6661Cortes, J., Rousselot, P., Kim, D.W., Ritchie, E., Hamerschlak, N., Coutre, S., Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis (2007) Blood, 109, pp. 3207-3213Hochhaus, A., Baccarani, M., Deininger, M., Apperley, J.F., Lipton, J.H., Goldberg, S.L., Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib (2008) Leukemia, 22, pp. 1200-1206Shah, N.P., Skaggs, B.J., Branford, S., Hughes, T.P., Nicoll, J.M., Paquette, R.L., Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency (2007) J Clin Invest, 117, pp. 2562-2569Cortes, J., Jabbour, E., Kantarjian, H., Yin, C.C., Shan, J., O'Brien, S., Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors (2007) Blood, 110, pp. 4005-4011Nowak, D., Ogawa, S., Muschen, M., Kato, M., Kawamata, N., Meixel, A., SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations (2010) Blood, 115, pp. 1049-1053Kaneta, Y., Kagami, Y., Katagiri, T., Tsunoda, T., Jin-Nai, I., Taguchi, H., Prediction of sensitivity to STI571 among chronic myeloid leukemia patients by genome-wide cDNA microarray analysis (2002) Jpn J Cancer Res, 93, pp. 849-856Villuendas, R., Steegmann, J.L., Pollan, M., Tracey, L., Granda, A., Fernandez-Ruiz, E., Identification of genes involved in imatinib resistance in CML: A gene-expression profiling approach (2006) Leukemia, 20, pp. 1047-1054Frank, O., Brors, B., Fabarius, A., Li, L., Haak, M., Merk, S., Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patients (2006) Leukemia, 20, pp. 1400-1407McWeeney, S.K., Pemberton, L.C., Loriaux, M.M., Vartanian, K., Willis, S.G., Yochum, G., A gene expression signature of CD34+ cells to predict major cytogenetic response in chronicphase chronic myeloid leukemia patients treated with imatinib (2010) Blood, 115, pp. 315-325McLean, L.A., Gathmann, I., Capdeville, R., Polymeropoulos, M.H., Dressman, M., Pharmacogenomic analysis of cytogenetic response in chronic myeloid leukemia patients treated with imatinib (2004) Clin Cancer Res, 10, pp. 155-165Huang, F., Reeves, K., Han, X., Fairchild, C., Platero, S., Wong, T.W., Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: Rationale for patient selection (2007) Cancer Res, 67, pp. 2226-2238Wang, X.D., Reeves, K., Luo, F.R., Xu, L.A., Lee, F., Clark, E., Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: Rationale for patient selection and efficacy monitoring (2007) Genome Biol, 8, pp. R255Perez, D.S., Hoage, T.R., Pritchett, J.R., Ducharme-Smith, A.L., Halling, M.L., Ganapathiraju, S.C., Long, abundantly expressed non-coding transcripts are altered in cancer (2008) Hum Mol Genet, 17, pp. 642-655Louro, R., Smirnova, A.S., Verjovski-Almeida, S., Long intronic noncoding RNA transcription: Expression noise or expression choice? (2009) Genomics, 93, pp. 291-298Fabbri, M., Garzon, R., Andreeff, M., Kantarjian, H.M., Garciamanero, G., Calin, G.A., MicroRNAs and noncoding RNAs in hematological malignancies: Molecular, clinical and therapeutic implications (2008) Leukemia, 22, pp. 1095-1105Calin, G.A., Croce, C.M., Chronic lymphocytic leukemia: Interplay between noncoding RNAs and protein-coding genes (2009) Blood, 114, pp. 4761-4770Reis, E.M., Nakaya, H.I., Louro, R., Canavez, F.C., Flatschart, A.V., Almeida, G.T., Antisense intronic non-coding RNA levels correlate to the degree of tumor differentiation in prostate cancer (2004) Oncogene, 23, pp. 6684-6692Brito, G.C., Fachel, A.A., Vettore, A.L., Vignal, G.M., Gimba, E.R., Campos, F.S., Identification of protein-coding and intronic noncoding RNAs down-regulated in clear cell renal carcinoma (2008) Mol Carcinog, 47, pp. 757-767Colombo, J., Fachel, A.A., De Freitas, C.M., Cury, P.M., Fukuyama, E.E., Tajara, E.H., Gene expression profiling reveals molecular marker candidates of laryngeal squamous cell carcinoma (2009) Oncol Rep, 21, pp. 649-663Tahira, A.C., Kubrusly, M.S., Faria, M.F., Dazzani, B., Fonseca, R.S., Maracaja-Coutinho, V., Long noncoding intronic RNAs are differentially expressed in primary and metastatic pancreatic cancer (2011) Mol Cancer, 10, p. 141Shah, N.P., Kantarjian, H.M., Kim, D.W., Rea, D., Dorlhiac-Llacer, P.E., Milone, J.H., Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronicphase chronic myeloid leukemia (2008) J Clin Oncol, 26, pp. 3204-3212Kantarjian, H., Cortes, J., Kim, D.W., Dorlhiac-Llacer, P., Pasquini, R., Dipersio, J., Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up (2009) Blood, 113, pp. 6322-6329Nakaya, H.I., Amaral, P.P., Louro, R., Lopes, A., Fachel, A.A., Moreira, Y.B., Genome mapping and expression analyses of human intronic noncoding RNAs reveal tissue-specific patterns and enrichment in genes related to regulation of transcription (2007) Genome Biol, 8, pp. R43Bolstad, B.M., Irizarry, R.A., Astrand, M., Speed, T.P., A comparison of normalization methods for high density oligonucleotide array data based on variance and bias (2003) Bioinformatics, 19, pp. 185-193Tusher, V.G., Tibshirani, R., Chu, G., Significance analysis of microarrays applied to the ionizing radiation response (2001) Proc Natl Acad Sci USA, 98, pp. 5116-5121Molinaro, A.M., Simon, R., Pfeiffer, R.M., Prediction error estimation: A comparison of resampling methods (2005) Bioinformatics, 21, pp. 3301-3307Beisvag, V., Junge, F.K., Bergum, H., Jolsum, L., Lydersen, S., Gunther, C.C., GeneTools-application for functional annotation and statistical hypothesis testing (2006) BMC Bioinformatics, 7, p. 470Soverini, S., Colarossi, S., Gnani, A., Castagnetti, F., Rosti, G., Bosi, C., Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain (2007) Haematologica, 92, pp. 401-404Jabbour, E., Kantarjian, H.M., Jones, D., Reddy, N., O'Brien, S., Garcia-Manero, G., Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors (2008) Blood, 112, pp. 4839-4842Fritzsche, F.R., Stephan, C., Gerhardt, J., Lein, M., Hofmann, I., Jung, K., Diagnostic and prognostic value of T-cell receptor gamma alternative reading frame protein (TARP) expression in prostate cancer (2010) Histol Histopathol, 25, pp. 733-739Tang, S., Bhatia, B., Maldonado, C.J., Yang, P., Newman, R.A., Liu, J., Evidence that arachidonate 15-lipoxygenase 2 is a negative cell cycle regulator in normal prostate epithelial cells (2002) J Biol Chem, 277, pp. 16189-16201Landais, S., Landry, S., Legault, P., Rassart, E., Oncogenic potential of the miR-106-363 cluster and its implication in human T-cell leukemia (2007) Cancer Res, 67, pp. 5699-5707Zhao, Y., Rangnekar, V.M., Apoptosis and tumor resistance conferred by Par-4 (2008) Cancer Biol Ther, 7, pp. 1867-1874Kukoc-Zivojnov, N., Puccetti, E., Chow, K.U., Bergmann, M., Ruthardt, M., Hoelzer, D., Prostate apoptosis response gene-4 (par-4) abrogates the survival function of p185(BCR-ABL) in hematopoietic cells (2004) Exp Hematol, 32, pp. 649-656L'Esperance, S., Popa, I., Bachvarova, M., Plante, M., Patten, N., Wu, L., Gene expression profiling of paired ovarian tumors obtained prior to and following adjuvant chemotherapy: Molecular signatures of chemoresistant tumors (2006) Int J Oncol, 29, pp. 5-24Quintas-Cardama, A., Kantarjian, H., Ravandi, F., O'Brien, S., Thomas, D., Vidal-Senmache, G., Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy (2009) Cancer, 115, pp. 2482-2490Anastassiadis, T., Deacon, S.W., Devarajan, K., Ma, H., Peterson, J.R., Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity (2012) Nat Biotechnol, 29, pp. 1039-1045Chan, D., Tyner, J.W., Chng, W.J., Bi, C., Okamoto, R., Said, J., Effect of dasatinib against thyroid cancer cell lines in vitro and a xenograft model in vivo (2012) Oncol Lett, 3, pp. 807-815Ponting, C.P., Oliver, P.L., Reik, W., Evolution and functions of long noncoding RNAs (2009) Cell, 136, pp. 629-641Hill, A.E., Hong, J.S., Wen, H., Teng, L., McPherson, D.T., McPherson, S.A., Micro-RNA-like effects of complete intronic sequences (2006) Front Biosci, 11, pp. 1998-2006Deininger, M.W., Goldman, J.M., Melo, J.V., The molecular biology of chronic myeloid leukemia (2000) Blood, 96, pp. 3343-3356Grosso, S., Puissant, A., Dufies, M., Colosetti, P., Jacquel, A., Lebrigand, K., Gene expression profiling of imatinib and PD166326-resistant CML cell lines identifies Fyn as a gene associated with resistance to BCR-ABL inhibitors (2009) Mol Cancer Ther, 8, pp. 1924-1933Kim, D.H., Kong, J.H., Byeun, J.Y., Jung, C.W., Xu, W., Liu, X., The IFNG (IFN-gamma) genotype predicts cytogenetic and molecular response to imatinib therapy in chronic myeloid leukemia (2010) Clin Cancer Res, 16, pp. 5339-5350Skorski, T., Kanakaraj, P., Nieborowska-Skorska, M., Ratajczak, M.Z., Wen, S.C., Zon, G., Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells (1995) Blood, 86, pp. 726-736Okabe, S., Tauchi, T., Ohyashiki, K., Characteristics of dasatinib-and imatinib-resistant chronic myelogenous leukemia cells (2008) Clin Cancer Res, 14, pp. 6181-6186Sillaber, C., Herrmann, H., Bennett, K., Rix, U., Baumgartner, C., Bohm, A., Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily (2009) Eur J Clin Invest, 39, pp. 1098-1109Nunoda, K., Tauchi, T., Takaku, T., Okabe, S., Akahane, D., Sashida, G., Identification and functional signature of genes regulated by structurally different ABL kinase inhibitors (2007) Oncogene, 26, pp. 4179-418